President Donald Trump, who appears increasingly frustrated by congressional Republicans’ inability to “repeal and replace” the Affordable Care Act, has led — since before he took office — the ballyhoo to let the law fail.
The pharmaceutical industry could see windfall profits from a little-noticed tweak to the insurance market tucked into the Trump administration’s draft executive order on drug prices, experts say.
With their party gaining control of both the White House and Congress, some Republican voters are growing hesitant about outright abolition of the Affordable Care Act and instead favoring a more circumspect approach of scaling it back, according to a poll released Thursday.
